Journal for ImmunoTherapy of Cancer

CORRECTION

Open Access

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Vaia Florou[1*], Andrew E. Rosenberg[1], Eric Wieder[1], Krishna V. Komanduri[1], Despina Kolonias[1], Mohamed Uduman[2], John C. Castle[2], Jennifer S. Buell[2], Jonathan C. Trent[1] and Breelyn A. Wilky[1]

Correction to: J ImmunoTher Cancer
https://doi.org/10.1186/s40425-019-0689-7

Following publication of the original article [1], the authors have reported that the following sentence "While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells."

should be replaced with

"Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8)."

Author details
[1]Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA. [2]Agenus Inc., 3 Forbes Road, Lexington, MA 02421, USA.

Published online: 06 November 2019

Reference

1. Florou, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J ImmunoTher Cancer. 2019;7:213. https://doi.org/10.1186/s40425-019-0689-7.

The original article can be found online at https://doi.org/10.1186/s40425-019-0689-7

* Correspondence: vaia.florou@hsc.utah.edu
[1]Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA
Full list of author information is available at the end of the article